Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Ella Castle

Esperion Therapeutics, Inc. ANN ARBOR, Mich., Dec. 18, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig, President and CEO, will deliver a corporate presentation on Wednesday, January 10, 2024, at 2:15 PM PT (5:15 PM ET). The […]

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

ANN ARBOR, Mich., Dec. 18, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig, President and CEO, will deliver a corporate presentation on Wednesday, January 10, 2024, at 2:15 PM PT (5:15 PM ET). The Esperion management team will also be hosting investor meetings during the conference.

To register for the live webcast, follow this link.

A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Esperion Contact Information: 
Investors:  
Alexis Callahan
[email protected]
(406) 539-1762 
  
Media:  
Tiffany Aldrich  
[email protected]
(616) 443-8438

Next Post

Interrupting Immune-Suppresser Treatment Could Boost Effects of COVID-19 Booster

New study findings announced that individuals with inflammatory conditions could improve their antibody response after COVID-19 booster vaccination if they stop treatment with immune suppressors for 2 weeks immediately after receiving the booster shot. Results were found in a large clinical trial that was conducted by researchers at the University […]
Interrupting Immune-Suppresser Treatment Could Boost Effects of COVID-19 Booster

Subscribe US Now

situs judi bola Daftar sekarang dengan cara klik link login slot via dana 24 jam terpercaya, join sekarang slot gacor online dengan pilihan platform game slot pragmatic play paling favorit tahun 2023. akun pro thailand idn poker